Agendia and Agilent to Jointly Develop New Diagnostics

Agendia BV (Amsterdam, The Netherlands), and Agilent Technologies, Inc. (Santa Clara, CA, USA), will collaborate to develop new in-vitro diagnostic tests. In addition, the two companies announced an agreement in which Agendia products will continue to be supplied on Agilent microarrays through December 31, 2011.

Agilent has been manufacturing the components for the Agendia assay since its inception in 2003. The financial terms of the agreement were not disclosed. In 2007, Agendia's MammaPrint, a molecular diagnostic tool developed to help physicians make informed decisions in treating breast cancer, became the first in-vitro diagnostic (IVD) microarray (MIA)-based diagnostic test cleared by the U.S. Food and Drug Administration (FDA; Rockville, MD, USA). The tests, manufactured on Agilent microarrays, are performed at Agendia's laboratory in The Netherlands. Agendia also offers DiscoverPrint, a gene expression-based service for improving the efficacy of clinical trials, and CupPrint, a diagnostic test designed to identify the origin of a metastasis in a cancer type called "cancer of unknown primary.” These are also manufactured using Agilent microarrays.
Agilent provides the microarrays used to analyze gene expression, microRNA, comparative genomic hybridization, and ChIP-on-chip.

Agendia develops and commercializes validated tests that assist healthcare professionals and pharmaceutical companies to determine the diagnosis, prognosis, and therapeutic responsiveness of cancers in individual patients.

Both companies will share information about their research into genetic biomarkers and jointly assess the commercial potential of each opportunity.


Related Links:
Agendia
Agilent Technologies
United States Food and Drug Administration